Tredje AP fonden Trims Position in AbbVie Inc. (NYSE:ABBV)
Tredje AP fonden Trims Position in AbbVie Inc. (NYSE:ABBV)
Tredje AP fonden decreased its position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 412,491 shares of the company's stock after selling 2,000 shares during the period. AbbVie accounts for approximately 1.4% of Tredje AP fonden's portfolio, making the stock its 12th largest holding. Tredje AP fonden's holdings in AbbVie were worth $66,869,000 at the end of the most recent quarter.
根據美聯社最近向美國證券交易委員會披露的信息，美聯社在第一季度減持了艾伯維公司的股票頭寸0.5%。在此期間出售了2,000股後，該公司持有該公司412,491股股票。AbbVie約佔Tredje AP Fonden投資組合的1.4%，使該股成為其第12大持股。截至最近一個季度末，Tredje AP Fonden在AbbVie持有的股份價值66,869,000美元。
Other institutional investors and hedge funds have also modified their holdings of the company. Summit Asset Management LLC grew its holdings in AbbVie by 6.2% during the 1st quarter. Summit Asset Management LLC now owns 4,459 shares of the company's stock valued at $723,000 after purchasing an additional 259 shares in the last quarter. Tectonic Advisors LLC boosted its stake in AbbVie by 14.5% during the 1st quarter. Tectonic Advisors LLC now owns 9,146 shares of the company's stock valued at $1,483,000 after acquiring an additional 1,161 shares during the last quarter. Proffitt & Goodson Inc. boosted its stake in AbbVie by 34.6% during the 1st quarter. Proffitt & Goodson Inc. now owns 1,191 shares of the company's stock valued at $193,000 after acquiring an additional 306 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in shares of AbbVie by 8.6% in the 1st quarter. Banque Cantonale Vaudoise now owns 59,133 shares of the company's stock worth $9,584,000 after buying an additional 4,667 shares during the last quarter. Finally, Capital Square LLC bought a new position in shares of AbbVie in the 1st quarter worth about $227,000. Hedge funds and other institutional investors own 67.03% of the company's stock.
其他機構投資者和對衝基金也調整了對該公司的持股。Summit Asset Management LLC在第一季度增持了6.2%的AbbVie股份。Summit Asset Management LLC現在擁有4459股該公司股票，價值72.3萬美元，上個季度又購買了259股。Structure Advisors LLC在第一季度將其在AbbVie的持股增加了14.5%。Structure Advisors LLC現在擁有該公司9,146股股票，價值1,483,000美元，在上個季度又購買了1,161股。Proffitt&Goodson Inc.在第一季度將其在AbbVie的持股增加了34.6%。Proffitt&Goodson Inc.在上個季度增持了306股後，現在持有1,191股該公司股票，價值19.3萬美元。第一季度，Canonale Vaudoise銀行將其在AbbVie股票的頭寸提高了8.6%。Canonale Vaudoise銀行現在擁有59,133股該公司股票，價值9,584,000美元，在上個季度又購買了4,667股。最後，Capital Square LLC在第一季度購買了價值約22.7萬美元的AbbVie新股票頭寸。對衝基金和其他機構投資者持有該公司67.03%的股份。
AbbVie Stock Up 0.2 %
AbbVie股價上漲0.2%
NYSE ABBV traded up $0.25 during trading hours on Friday, reaching $139.17. 83,173 shares of the company's stock were exchanged, compared to its average volume of 6,025,083. The company's 50-day moving average is $147.75 and its two-hundred day moving average is $150.05. AbbVie Inc. has a one year low of $105.56 and a one year high of $175.91. The company has a debt-to-equity ratio of 3.89, a quick ratio of 0.71 and a current ratio of 0.82. The company has a market capitalization of $245.93 billion, a price-to-earnings ratio of 19.68, a price-to-earnings-growth ratio of 3.96 and a beta of 0.70.
紐約證券交易所ABBV在週五的交易時間裏上漲了0.25美元，達到139.17美元。該公司股票成交量為83,173股，而其平均成交量為6,025,083股。該公司50日移動均線切入位在147.75美元，200日移動均線切入位在150.05美元。AbbVie Inc.的一年低點為105.56美元，一年高位為175.91美元。該公司的負債權益比率為3.89，速動比率為0.71，流動比率為0.82。該公司市值2,459.3億美元，市盈率19.68倍，市盈率3.96倍，貝塔係數0.70。
AbbVie Announces Dividend
AbbVie宣佈分紅
The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be given a $1.41 dividend. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Thursday, July 14th. AbbVie's payout ratio is currently 79.89%.
該公司最近還宣佈了季度股息，將於8月15日(星期一)支付。7月15日(星期五)登記在冊的投資者將獲得1.41美元的股息。這意味着年化股息為5.64美元，股息收益率為4.05%。除股息日期為7月14日星期四。AbbVie的派息率目前為79.89%。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several equities analysts have commented on the stock. Piper Sandler lowered their target price on shares of AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Barclays raised their target price on shares of AbbVie from $150.00 to $174.00 and gave the stock an "equal weight" rating in a report on Tuesday, April 12th. SVB Leerink started coverage on shares of AbbVie in a report on Monday, May 23rd. They set an "underperform" rating and a $140.00 price target for the company. UBS Group reduced their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a research note on Monday. Finally, The Goldman Sachs Group lifted their target price on shares of AbbVie from $122.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $159.29.
幾位股票分析師對該股發表了評論。派珀·桑德勒在7月29日星期五的一份研究報告中將艾伯維的目標股價從160.00美元下調至155.00美元。巴克萊將艾伯維股票的目標價從150.00美元上調至174.00美元，並在週二的一份報告中給予該股“同等權重”的評級。SVB Leerink在5月23日星期一的一份報告中開始報道AbbVie的股票。他們為該公司設定了“表現不佳”的評級和140.00美元的目標價。瑞銀集團週一在一份研究報告中將艾伯維股票的目標價從154.00美元下調至146.00美元，並將該公司的評級定為“中性”。最終，高盛夫婦將艾伯維股票的目標價從122.00美元上調至140.00美元，並在週二的一份研究報告中給出了該公司“中性”的評級。一名投資分析師對該股的評級為賣出，6名分析師給予持有評級，10名分析師給予買入評級，一名分析師給予該公司強烈買入評級。根據MarketBeat的數據，該公司目前的平均評級為“中等買入”，平均目標價為159.29美元。
Insider Activity at AbbVie
艾伯維的內幕活動
In other news, Vice Chairman Michael Severino sold 100,000 shares of AbbVie stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the sale, the insider now directly owns 152,103 shares of the company's stock, valued at $23,492,308.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company's stock, valued at $2,576,565. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Vice Chairman Michael Severino sold 100,000 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the completion of the transaction, the insider now directly owns 152,103 shares in the company, valued at $23,492,308.35. The disclosure for this sale can be found here. Insiders have sold 363,761 shares of company stock valued at $55,528,771 over the last ninety days. 0.08% of the stock is owned by corporate insiders.
在其他新聞方面，副董事長邁克爾·塞維裏諾在5月16日星期一的交易中出售了10萬股AbbVie股票。股票以154.45美元的平均價格出售，總成交金額為15,445,000.00美元。出售後，這位內部人士現在直接擁有152,103股該公司股票，價值23,492,308.35美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過美國證券交易委員會網站訪問。在AbbVie的其他新聞中，執行副總裁Henry O.Gosebruch在5月16日星期一的一筆交易中出售了83,960股公司股票。這些股票的平均價格為155.00美元，總價值為13,013,800.00美元。交易完成後，執行副總裁總裁現在直接持有該公司16,623股股票，價值2576,565美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，可以通過以下鏈接訪問該文件。此外，副董事長邁克爾·塞維裏諾在5月16日星期一的一次交易中出售了10萬股該公司的股票。這些股票以154.45美元的平均價格出售，總成交金額為15,445,000.00美元。交易完成後，這位內部人士現在直接擁有該公司152,103股，價值23,492,308.35美元。此次拍賣的披露信息可在此處找到。在過去的90天裏，內部人士已經出售了363,761股公司股票，價值55,528,771美元。0.08%的股份由企業內部人士持有。
AbbVie Profile
AbbVie個人資料
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- BJ's Wholesale Club Stock Has More Room to Grow
- 3 Hotel Stocks to Consider Checking into After Earnings
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望，而且它很便宜
- 北京批發俱樂部庫存有更大的增長空間
- 盈利後考慮登記的3家酒店股票
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。